Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
alprazolam
|
| gptkbp:brand |
alprazolam
|
| gptkbp:controlledSubstanceSchedule |
Schedule IV (US)
|
| gptkbp:drugClass |
benzodiazepine
|
| gptkbp:FDAApproved |
yes
|
| gptkbp:form |
orally disintegrating tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Niravam
|
| gptkbp:manufacturer |
gptkb:Pfizer
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
dizziness
fatigue drowsiness memory impairment |
| gptkbp:usedFor |
gptkb:panic_disorder
anxiety disorders |
| gptkbp:bfsParent |
gptkb:Alprazolam
|
| gptkbp:bfsLayer |
7
|